Literature DB >> 31535580

The evolving role of radiotherapy in non-small cell lung cancer.

Sean Brown1, Kathryn Banfill1,2, Marianne C Aznar1,2,3, Philip Whitehurst4, Corinne Faivre Finn1,2.   

Abstract

Lung cancer is the most commonly diagnosed cancer and biggest cause of cancer mortality worldwide with non-small cell lung cancer (NSCLC) accounting for most cases. Radiotherapy (RT) plays a key role in its management and is used at least once in over half of patients in both curative and palliative treatments. This narrative review will demonstrate how the evolution of RT for NSCLC has been underpinned by improvements in RT technology. These improvements have facilitated geometric individualization, increasingly accurate treatment and now offer the ability to deliver truly individualized RT. In this review, we summarize and discuss recent developments in the field of advanced RT in early stage, locally advanced and metastatic NSCLC. We highlight limitations in current approaches and discuss future potential treatment strategies for patients with NSCLC.

Entities:  

Mesh:

Year:  2019        PMID: 31535580     DOI: 10.1259/bjr.20190524

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  22 in total

1.  Combination of Palliative Thoracic Radiotherapy With Bevacizumab for Stage IV Nonsquamous NSCLC: Is There Any Impact of Time Interval on Survival?

Authors:  Weigang Xiu; Xiaotong Guo; Min Yu; Yanying Li; Yong Xu; Jiang Zhu; Jingjing Luo
Journal:  Clin Med Insights Oncol       Date:  2022-06-24

2.  An Institutional Audit of Maximum Heart Dose in Patients Treated With Palliative Radiotherapy for Non-small Cell Lung Cancer.

Authors:  Carsten Nieder; Kristian S Imingen
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

3.  PARP inhibitor niraparib as a radiosensitizer promotes antitumor immunity of radiotherapy in EGFR-mutated non-small cell lung cancer.

Authors:  N Zhang; Y Gao; Z Zeng; Y Luo; X Jiang; J Zhang; J Li; J Zhang; Y Gong; C Xie
Journal:  Clin Transl Oncol       Date:  2021-03-28       Impact factor: 3.405

4.  The HNF1A-AS1/miR-92a-3p axis affects the radiosensitivity of non-small cell lung cancer by competitively regulating the JNK pathway.

Authors:  Zhiyu Wang; Liang Liu; Yuankun Du; Yuan Mi; Lei Wang
Journal:  Cell Biol Toxicol       Date:  2021-03-23       Impact factor: 6.691

Review 5.  Thoracic radiotherapy in small cell lung cancer-a narrative review.

Authors:  Antonin Levy; Angela Botticella; Cécile Le Péchoux; Corinne Faivre-Finn
Journal:  Transl Lung Cancer Res       Date:  2021-04

6.  Probing thoracic dose patterns associated to pericardial effusion and mortality in patients treated with photons and protons for locally advanced non-small-cell lung cancer.

Authors:  Laura Cella; Serena Monti; Ting Xu; Raffaele Liuzzi; Arnaldo Stanzione; Marco Durante; Radhe Mohan; Zhongxing Liao; Giuseppe Palma
Journal:  Radiother Oncol       Date:  2021-05-09       Impact factor: 6.901

7.  Up-regulation of VANGL1 by IGF2BPs and miR-29b-3p attenuates the detrimental effect of irradiation on lung adenocarcinoma.

Authors:  Chun-Cheng Hao; Cui-Yang Xu; Xin-Yu Zhao; Jia-Ning Luo; Gang Wang; Li-Hong Zhao; Xiaofeng Ge; Xiao-Feng Ge
Journal:  J Exp Clin Cancer Res       Date:  2020-11-23

8.  Palliative Thoracic Radiotherapy for Non-Small Cell Lung Cancer in Outpatients: Reasons for Unplanned Hospitalization and Its Impact on Survival.

Authors:  Carsten Nieder; Kristian S Imingen; Ellinor Haukland
Journal:  J Clin Med Res       Date:  2021-03-19

9.  A clinicopathologic analysis of microscopic extension in small cell lung cancer and lung adenocarcinoma: Determination of clinical target volume with precise radiotherapy.

Authors:  Liwei Gao; Xiuhong Wang; Xiongtao Yang; Runchuan Gu; Guangying Zhu; Xianshu Gao
Journal:  Thorac Cancer       Date:  2021-05-24       Impact factor: 3.500

Review 10.  Review of Deep Learning Based Automatic Segmentation for Lung Cancer Radiotherapy.

Authors:  Xi Liu; Kai-Wen Li; Ruijie Yang; Li-Sheng Geng
Journal:  Front Oncol       Date:  2021-07-08       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.